GlassScriptPhysician profile
Andrew O Baddoo
NPI 1881653608
$10,989.69
in general payments reported to CMS, 2019-2025
35 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $1,389 · 2021: $1,414 · 2022: $1,807 · 2023: $1,508 · 2024: $1,857 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,778 · Education: $55.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,778.23 |
| Education | $55.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,663.89 | 2019-2023 | Krystexxa |
| Amgen INC. | $1,323.71 | 2019-2025 | Krystexxa, Repatha, Tavneos |
| Astrazeneca Pharmaceuticals LP | $1,223.47 | 2019-2024 | Farxiga, Lokelma |
| Ani Pharmaceuticals, INC. | $908.69 | 2022-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $597.17 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Vifor Pharma, INC. | $564.20 | 2019-2024 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $538.06 | 2019-2024 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $504.37 | 2021-2025 | |
| Travere Therapeutics, INC. | $435.63 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $411.65 | 2019-2023 | Verquvo, Segluromet, Steglatro |
| Mallinckrodt Hospital Products INC. | $394.31 | 2020-2025 | Acthar |
| Ardelyx, INC. | $386.93 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Lilly USA, LLC | $296.79 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $260.24 | 2019-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.10 | 2019-2025 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $214.98 | 2021-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $195.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $186.44 | 2019-2024 | |
| Calliditas Therapeutics US INC. | $154.92 | 2023-2024 | Tarpeyo |
| Sanofi-Aventis U.S. LLC | $72.27 | 2020-2022 | |
| Daiichi Sankyo INC. | $64.16 | 2020-2021 | |
| Glaxosmithkline, LLC. | $60.84 | 2021-2025 | Benlysta |
| Arbor Pharmaceuticals, INC. | $52.50 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $40.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $35.10 | 2019-2020 | |
| Allergan, INC. | $33.21 | 2020-2021 | |
| Akebia Therapeutics INC | $32.37 | 2019-2025 | Vafseo |
| Cardiovascular Systems INC. | $18.54 | 2020 | |
| Dexcom, INC. | $17.00 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $16.91 | 2023 | Gvoke Hypopen |
| Pfizer INC. | $14.00 | 2021 | |
| Fresenius USA Marketing, INC. | $12.96 | 2020 | |
| Amarin Pharma, INC. | $11.74 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.11 | 2019 | |
| Global Blood Therapeutics, INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Baddoo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.